A2i Therapeutics
Novel Small-molecule Immuno-oncology Agents
Company Overview
Snapshot
Founded in November 2020, A2i Therapeutics operated with 1–10 employees. The company secured funding across two rounds from RMGP Biopharma Investment Fund and FutuRx. In November 2020, A2i Therapeutics launched as a joint venture between FutuRx and Atomwise, focusing on immuno-oncology.
Business overview
A2i Therapeutics is a biotechnology company focused on developing novel small-molecule immuno-oncology agents. The company leverages artificial intelligence for small-molecule drug discovery, specifically targeting key proteins involved in controlling the innate immune response. It operates within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals, and aims to address critical needs in oncology and immunology.
Strategic signal
In December 2020, A2i Therapeutics was launched as a joint venture between FutuRx and Atomwise, with funding from leading biopharma VCs and the Israeli Innovation Authority. This collaboration signals a strategic move to combine Atomwise's AI-driven drug discovery platform with FutuRx's expertise in early-stage therapeutic technologies, aiming to accelerate the development of innovative immuno-oncology treatments.
Company Intelligence Q&A
- What is A2i Therapeutics' primary focus?
- A2i Therapeutics is focused on developing novel small-molecule immuno-oncology agents, leveraging artificial intelligence for drug discovery to target key proteins involved in the innate immune response.
- When was A2i Therapeutics founded?
- A2i Therapeutics was founded in November 2020.
- Who are the key partners in the formation of A2i Therapeutics?
- A2i Therapeutics was formed as a joint venture between FutuRx, an Israeli biotechnology incubator, and Atomwise, a US-based company specializing in AI for small-molecule drug discovery.
- Which investors participated in A2i Therapeutics' funding round?
- In November 2020, A2i Therapeutics received funding from RMGP Biopharma Investment Fund and FutuRx.
- Did A2i Therapeutics receive any non-equity funding?
- In November 2020, A2i Therapeutics secured a grant from the Israel Innovation Authority.